Financial Performance - In 2022, the company achieved operating revenue of 195.25 million yuan, a year-on-year increase of 26.96% [2] - The net profit attributable to shareholders was 35.89 million yuan, with a decrease of 19.73% [3] - The net profit after deducting non-recurring gains and losses was 23.94 million yuan, showing a growth of 2.67% [3] - In Q1 2023, the company reported operating revenue of 44.49 million yuan, a year-on-year increase of 19.35% [3] - The net profit attributable to shareholders in Q1 2023 was 7.82 million yuan, up 9.19% [3] Product Revenue Breakdown - The main revenue sources were artificial dura mater (74.09%) and craniofacial repair systems (19.36%) [3] - The absorbable regenerated oxidized cellulose hemostatic products were used in over 50,000 cases domestically and internationally [3] - Domestic revenue reached 159.28 million yuan, growing by 20.99%, while international revenue was 35.98 million yuan, increasing by 62.51% [3] R&D and Market Strategy - R&D investment in 2022 was 40.57 million yuan, accounting for 20.78% of operating revenue [5] - The company aims to leverage centralized procurement policies to enhance market expansion capabilities in neurosurgery [4] - The company has established good relationships with over 700 distributors and its products are available in over 1,400 hospitals domestically and in more than 80 countries and regions internationally [3] Future Outlook - The company plans to enhance its product line and brand influence through a multi-product synergy strategy [4] - The development of absorbable hemostatic products is expected to increase market penetration and competitiveness against imported brands [4] - The company is focused on expanding its global market presence to boost brand recognition and overall sales [6]
迈普医学(301033) - 2023年5月17日投资者关系活动记录表